Oral Probiotic Containing Streptococcus salivarius K12 and Lactobacillus brevis CD2 for Preventing Bacterial Pneumonia in Severe COVID-19: Randomized Clinical Trial.
- 2025-11-12
- RCT · n = 60
- The journal of contemporary dental practice 26(10)
- Jonathan R Lauxen
- Sidia M Callegari-Jacques
- Augusto S Mombelli
- Amanda Prando
- Tiago T Simon
- Fernando Fornari
- PubMed: 41526312
- DOI: 10.5005/jp-journals-10024-3954
- High evidence
- Clinical
The 14-day illness-severity status did not differ between groups.
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 2 billion colony-forming units every 8 hours